Learn about all myeloma happenings on the new Myeloma Crowd site: the first comprehensive site for myeloma patients and caregivers. Dr. Stephen Russell, MD, PhD Mayo Clinic Rochester Interview Date: May 30, 2014

 Dr. Stephen Russell, a leader in gene and virus therapy of the Mayo Clinic, shares the detail about the recent success of the use of an engineered measles vaccine for myeloma in heavily pre-treated patients who were refractory to existing myeloma therapies. He describes in detail the creation of the therapy, the first trial, side effects, results of the treatment and the differences in their response. This is the very first time any patient with a disseminated cancer (not a localized cancer) has had a complete response after IV administration of a virus and is a historic achievement. However, Dr. Russell says that it is not yet a one-shot-wonder but only a step in that direction. The Phase II trial for 20 patients will begin in September and is only inhibited by the need to produce the virus. Manufacturing is now happening at the Mayo Clinic but they are looking for expanded manufacturing options. The Phase II trial will use the engineered measles vaccine only without the addition of other therapies. He describes the tests for eligibility and shares his opinion on the future of this type of therapy. This is a remarkable discovery by an outstanding researcher that brings hope to a new class of therapies for myeloma treatment.   The live mPatient Myeloma Radio podcast with Dr. Stephen Russell